Phlebology > Volume 22, Number 6 > Pp. 299-302

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bergan, J Articles by Cheng, V Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Original articles

Foam sclerotherapy of venous malformations

J Bergan and V Cheng

Vein Institute of La Jolla, La Jolla, San Diego, CA, USA; Department of Surgery, UCSD School of Medicine, San Diego, CA, USA; Vein Institute of La Jolla, La Jolla, San Diego, CA, USA; Department of Surgery, UCSD School of Medicine, San Diego, CA, USA

Venous malformations may occur either as localized or segmental lesions. Radiologic imaging defines the extent of involvement but magnetic resonance imaging is the best modality: it gives a bright hypersignal on T2-weighted spin-echo sequences.

During a 30-month period, 1427 patients were investigated for venous disorders and 1% were found to have venous angiomata (9 women and 5 men). The age range was 15 to 76 years (mean 30.8 ± 18.6 years). Foam was produced by the Tessari technique using 1% or 2% concentration of polidocanol. The duplex Doppler was used for ultrasound guidance to insure intravenous flow of foam and to monitor effects of treatment.

A goal of pain-free healing of ulcers or cosmetic improvement was set for each patient. The mean number of treatments was 3.6 ± 2.8 (range 1–10). Pain-free healing was achieved in patients with non-healing ulcerations and cosmetically, all of the patients were improved. Sclerosant foam is useful in treating low-flow venous malformations.

Key Words: VEINS • MALFORMATIONS • KLIPPEL-TRENAUNAY SYNDROME • SCLEROTHERAPY • POLIDOCANOL

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?